Labcorp Holdings Inc. LH
Composite 54/100; the shares have moved about 23% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 40/100 — a slight mark against it.
Momentum ranks 71/100 — a moderate point in its favour. Balance-sheet strength ranks 61/100 — a slight point in its favour. Growth ranks 60/100 — a slight point in its favour.
Valuation ranks 40/100 — a slight mark against it. Income ranks 43/100 — a slight mark against it.
What the company does Labcorp Holdings Inc. (LH) provides diagnostic and esoteric laboratory services, including blood chemistry analyses, genetic testing, oncology, infectious disease, and employer health programs. Its Biopharma Laboratory Services segment supports drug development with specialized assays and digital pathology solutions.
Key financials Revenue grew 7.2% with net margins at 7.0%. ROE is 11.7%, ROA 5.5%, and ROCE 8.9%. Operating margin is 12.2% and gross margin 28.9%. Debt/Equity is 0.79 and interest coverage 6.41x.
Stock health Sideravia scores: overall 54.7 (weak quality), growth 61.8, strength 60.5, valuation 40.2, momentum 70.4, income 42.6. Piotroski F-Score 7/9, Altman Z 3.38. RSI(14) is 72.70.
Price vs fair value LH trades at a discount of 2.20% to the analyst mean target of 337.75. - Recent 3-month momentum is 30.61% (Sideravia). - RSI(14) at 72.70 signals overbought conditions (Sideravia). - Forward P/E 17.73 vs trailing 26.66 indicates earnings recovery expectations (Sideravia). - Analyst mean target implies 2.20% upside from current price (analyst mean target).
Looking forward Forward PEG of 0.35 suggests valuation support relative to growth. EBITDA growth and margin stability will be key to sustaining momentum. Dividend yield is 0.9% with a conservative payout ratio of 16.5%.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.